Company Overview

PRIME exits and American Healthcare Capital are proud to be the exclusive representative of a rapidly emerging medical technology company with a portfolio of Ips for sale. The company has developed a breakthrough non-invasive cardiopulmonary monitoring system that integrates seamlessly with standard ventilators, providing real-time, critical patient data at the bedside. This proprietary system addresses a multi-billion-dollar market opportunity, particularly in Intensive Care Units (ICUs), emergency care, and telehealth applications. The company has invested years in R&D and is now at an inflection point, seeking a strategic investor to propel the technology into full commercialization.

Investment Highlights

• First-of-its-Kind Technology: The system is the only known solution capable of delivering real-time, bedside measurements of ventilation-perfusion mismatch, pulmonary blood flow, functional residual capacity, and dead space analysis—all without invasive procedures.

• Global Market Potential: The solution addresses a $4B+ market, with applications in hospitals, ICUs, and remote patient monitoring.

• Regulatory & Clinical Traction: The company has ongoing clinical validation with multiple leading hospitals across North America, Europe, and the Middle East.

• Highly Scalable Revenue Model: The system consists of a capital equipment component and a recurring revenue model through per-patient disposable.

• Robust Intellectual Property Portfolio: The company owns a strong patent portfolio (17+ years of protection) with multiple issued and pending patents.

• Investment Opportunity: The buyer/investor will acquire full intellectual property rights and fund the next phase of growth, which includes regulatory approvals, manufacturing scale-up, and commercialization.

Ideal Investor Profile

• MedTech corporations seeking a high-impact addition to their portfolio

• Private equity groups with a focus on healthcare technology and life sciences

• Strategic investors interested in early-stage, high-growth medical innovations

• Companies expanding or already present in Canada seeking a large tax credit

Asking Price and the Next Step

The owner is open to majority sale and equity rollover to accelerate the company’s commercialization and achieve market dominance. The asking price and company valuation are to be determined through discussion and negotiation. Up to $18.5 million in tax credit is available to qualified investors